AAV, or adeno-associated virus, is a viral vector commonly used in gene therapy. In recent years, with the deepening of gene therapy research, the demand for AAV has gradually increased. However, the production process of AAV is complex, low yield, and susceptible to various factors. Therefore, how to screen suitable AAV vectors efficiently, quickly and cost-effectively has become an urgent problem to be solved in the gene therapy industry.
Join us for a webinar on "Application of Twist Synthetic Biology Products for AAV Discovery and Optimization" on January 11, 2024, brought to you by Dr. Ren Sheng, General Manager of DecodeGene and Director of Gene Therapy at Cyagen, and Zhenzhen Xiong, Senior Field Application Scientist at Twist.
Seminar Highlights:
- How to screen suitable AAV vectors efficiently, quickly and cost-effectively?
- How to improve the druggability of gene therapy drugs using AAV as a delivery vehicle?
- Twist高通量DNA合成平台介绍;
- Based on the platform, the characteristics and advantages of the products developed and applied to the key processes of synthetic biology are introduced, as well as the prominent role in the key processes.
Date: 11 January 2024 (Thursday)
Time: 10:00 a.m
*If you are unable to watch the live stream,
A link to the replay will be sent to your registered email address after the meeting
About the Speaker
------------------------------------------------
Dr. Ren Sheng
General Manager of Decoded Gene
Director of Gene Therapy at Cyagen
He has participated in China's first ophthalmic gene therapy project and entered the clinic, applied for more than 20 gene therapy related to gene therapy, obtained more than 10 authorizations, and discovered a number of novel AAV variants that efficiently infect ophthalmology and nerves.
---------------------------------------------------
Kuma Shinjin
Senior Application Scientist
Twist Bioscience
He is mainly responsible for providing pre-sales and after-sales technical support for next-generation sequencing targeting solutions, as well as providing technical support to customers for synthetic biology solutions such as gene synthesis and oligonucleotide synthesis. Prior to joining Twist Bioscience, he worked as a technical specialist at Qiagen and has extensive experience in nucleic acid extraction, library preparation, and NGS targeted capture.
About us
Twist Bioscience is a leading and fast-growing synthetic biology and genomics company developing disruptive DNA synthesis platforms that advance the industrialization of bioengineering. At the heart of the platform is a patented technology that pioneers a new way to manufacture synthetic DNA by "writing" DNA on silicon chips. Twist is leveraging its unique technology to manufacture a wide range of synthetic DNA-based products, including synthetic genes, next-generation sequencing (NGS) preparation tools, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital DNA data storage and biologics drug discovery. Twist manufactures products for use in many industries, including healthcare, industrial chemicals, agriculture, and academic research.
For detailed information about products and services, please leave a message in the WeChat background and we will get in touch with you as soon as possible.